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Trisomy 21 (T21) causes Down syndrome (DS), affecting immune and neurological function
by ill-defined mechanisms. Here we report a large metabolomics study of plasma and cer-
ebrospinal fluid, showing in independent cohorts that people with DS produce elevated levels
of kynurenine and quinolinic acid, two tryptophan catabolites with potent immunosuppressive
and neurotoxic properties, respectively. Immune cells of people with DS overexpress IDO1,
the rate-limiting enzyme in the kynurenine pathway (KP) and a known interferon (IFN)-
stimulated gene. Furthermore, the levels of IFN-inducible cytokines positively correlate with
KP dysregulation. Using metabolic tracing assays, we show that overexpression of IFN
receptors encoded on chromosome 21 contribute to enhanced IFN stimulation, thereby
causing IDO1 overexpression and kynurenine overproduction in cells with T21. Finally, a
mouse model of DS carrying triplication of IFN receptors exhibits KP dysregulation. Together,
our results reveal a mechanism by which T21 could drive immunosuppression and
neurotoxicity in DS.
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Down syndrome (DS) is caused by triplication of chro-mosome 21 (chr21), which occurs in ~1 in 700 live births,representing the most common chromosomal abnorm-
ality in the human population1. Trisomy 21 (T21) impacts mul-
tiple organ systems during development and causes an altered
disease spectrum in people with DS, significantly increasing
their risk of developing Alzheimer’s disease (AD)2, leukemias3,
some respiratory infections4, and numerous autoimmune
conditions1,5–8, while protecting them from solid malignancies3,9.
However, DS-associated phenotypes are highly variable among
individuals with DS, even for conserved phenotypes such as
cognitive impairment and predisposition to early-onset AD10,11.
Therefore, a deeper understanding of the mechanisms driving
such phenotypic variation could illuminate not only mechanisms
of pathogenesis, but also opportunities for diagnostics and ther-
apeutic strategies to serve this population. Furthermore, these
mechanistic insights could also benefit larger numbers of indi-
viduals in the typical population affected by the medical condi-
tions that are modulated, either positively or negatively, by T21.
In order to identify molecular pathways that could contribute
to both the altered disease spectrum experienced by the popula-
tion with DS and the inter-individual phenotypic variation, our
group previously analyzed transcriptomes12 and circulating pro-
teomes13 from several cohorts of individuals with DS compared
with euploid individuals (D21, controls). These efforts revealed
that multiple cell types from people with DS show transcriptional
signatures indicative of constitutive activation of the interferon
(IFN) response12, which could be explained by the fact that four
of the six IFN receptors (IFNRs) are encoded on chr21: the two
Type I IFNR subunits (IFNAR1, IFNAR2), one of the Type II
IFNRs (IFNGR2), and IL10RB, which serves both as a Type III
IFNR subunit and a subunit of the receptors for interleukin (IL)-
10, IL-22, and IL-2614. Furthermore, plasma proteomics analyses
demonstrated that people with DS show signs of chronic auto-
inflammation13, including elevated levels of potent inflammatory
cytokines with known ties to IFN signaling (e.g., IL-6, tumor
necrosis factor (TNF-α), MCP-1). However, it remains to be
defined how this obvious immune dysregulation contributes to
DS-associated phenotypes, including the diverse immune and
neurological manifestations of T21. Recent advances in the field
of immunometabolism have highlighted a critical role for circu-
lating levels of certain metabolites in the regulation of immune
function and inflammation15. To gain further insight into this
area, we investigated metabolic changes caused by T21 in the
plasma and cerebrospinal fluid (CSF) of people with DS.
Here we report the results of a large plasma metabolomics
study of individuals with DS from multiple cohorts. Initially, we
performed an exploratory untargeted analysis of two cohorts via
ultra-high-pressure liquid chromatography coupled to high-
resolution mass spectrometry (UHPLC-HRMS) technology. The
most significantly dysregulated metabolite identified was quino-
linic acid (QA), a tryptophan (TRP) catabolite with well-
characterized neurotoxicity, which has been repeatedly asso-
ciated with diverse neurological disorders, and which is produced
by activation of the kynurenine (KYN) pathway (KP). Indeed,
people with DS have elevated QA, KYN, and KYN/TRP ratio, all
established markers of KP activation. We then validated these
findings using absolute quantification methods in additional
cohorts, in which we confirmed the upregulation of KYN and QA
in both the plasma and CSF of people with DS. We found that
circulating immune cells of individuals with T21 show significant
overexpression of indoleamine 2,3-dioxygenase 1 (IDO1), the
rate-limiting enzyme in the KP, and a known IFN-stimulated
gene (ISG) induced by all three types of IFN signaling. Using cell-
based metabolic assays, we demonstrated that IFN-α stimulation
leads to super-induction of IDO1 and hyperactivation of the KP
in cells with T21, and this requires overexpression of both Type I
IFNR subunits encoded on chr21. Furthermore, circulating levels
of key inflammatory cytokines, including IP-10, IL-10, and TNF-
α, are positively correlated with KP activation in people with DS.
Finally, we show that a mouse model of DS carrying triplication
of the IFNR gene cluster, Dp(16)1/Yey, shows increased levels of
KYN relative to wild-type (WT) littermates. Given the well-
established neurotoxicity of QA, the association of KP dysregu-
lation with a wide range of neurological conditions, as well as the
immunosuppressive function of KYN, our results point to KP
activation as a potential contributing factor to neurological and
immunological phenotypes in DS.
Results
Trisomy 21 induces the kynurenine pathway. To identify
metabolic pathways that are consistently dysregulated by T21, we
collected plasma samples from two fully independent cohorts: the
Translational Nexus Clinical Data Registry and Biobank (referred
hereto as Cohort 1) and the Crnic Institute’s Human Trisome
Project (www.trisome.org, NCT02864108, referred hereto as
Cohort 2). Cohort 1 included 49 individuals with T21 and 49
euploid (D21) individuals, whereas Cohort 2 consisted of 26 T21
and 41 D21 (see demographics information in Supplementary
Data 1). Although Cohort 1 was balanced for karyotype but
imbalanced for age, Cohort 2 was more age-balanced, with a bias
towards females in both groups. When the two cohorts are
combined, age, sex, and karyotype are more evenly distributed,
which prompted us to analyze the cohorts both individually and
in combination. It should be noted that our protocol excluded
participants with recent or active infections.
To determine metabolite abundance, we performed an
exploratory UHPLC-HRMS-based metabolomics on plasma
samples from each cohort. The combined analysis workflow is
outlined in Supplementary Fig. 1a with details available in the
Methods. This approach led to the identification of 91 Kyoto
Encyclopedia of Genes and Genomes (KEGG)-annotated meta-
bolites detected in both cohorts in >90% of the samples from at
least one karyotype. To identify the metabolites that were
consistently differentially abundant between people with and
without DS, we applied a robust linear model-fitting approach
that accounted for age and sex16 to data from each of the cohorts
(Supplementary Data 2–4). We observed both differences and
overlaps in the differential metabolite profiles when analyzing
Cohorts 1 and 2 individually. However, due to the relative nature
of the quantification determined by exploratory UHPLC-HRMS,
we observed an overall difference in the distributions of
metabolite abundances between cohorts (Supplementary Fig. 1b).
Therefore, to mitigate imbalances within the separate cohorts and
to increase statistical power, we completed a combined cohort
analysis by modeling age and sex covariates, along with fitting
each cohort as a batch effect. Using this linear model fit, the
distributions of metabolite abundance overlap and are thus
comparable (Supplementary Fig. 1c).
When the combined total of 165 samples in the two cohorts
were analyzed for the 91 metabolites using this linear model fit
accounting for age, sex, and cohort, we identified 29 metabolites
with relative levels that were significantly different according to a
false discovery rate (FDR)-adjusted p-value on a Student’s t-test
of 0.0517 (Fig. 1a and Supplementary Data 4). Consistent with
earlier reports18,19, L-serine and L-tyrosine were found to be
depleted in people with DS (Fig. 1a and Supplementary Fig. 1d).
Depletion of L-homocysteine (Fig. 1a and Supplementary Fig. 1d),
which has also been previously observed in people with DS20,
could be attributed to the localization of the cystathionine-β-
synthase gene (CBS) on chr21. Among the upregulated
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Fig. 1 Trisomy 21 induces the kynurenine pathway. a Differentially abundant metabolites in plasma samples from individuals with T21 were identified using
a linear model adjusting for age, sex, and cohort. Metabolites that increased in the T21 group are shown in red and metabolites that decreased in the T21
group are blue. The horizontal gray line represents an adjusted p-value of 0.05. n= 165 independent samples, 75 with T21. b Boxplots showing the relative
quantification in log2-adjusted intensity for significantly differentially abundant metabolites. p-values were calculated using the linear model from a and the
FDR method for multiple testing correction. c Boxplots showing log2-adjusted ratios as indicated. p-values were calculated using an unmoderated t-test on
the linear model in a. d Boxplots showing concentrations of kynurenine and quinolinic acid, as well as the ratio of kynurenine to tryptophan calculated from
the absolute quantification of these metabolites in Cohort 3, n= 124 independent samples, 72 with T21. e Scatter plots comparing kynurenine/tryptophan
ratios with concentrations of quinolinic acid from Cohort 3. Spearman’s rho (ρ) and FDR-corrected p-values are indicated. f Boxplots showing
concentrations of tryptophan, L-formylkynurenine, and kynurenine, as well as the ratio of kynurenine to tryptophan calculated from the absolute
quantification of these metabolites in the CSF of Cohort 4, n= 100 independent samples, 50 with T21. All boxplots show median, 25th, and 75th percentile
values. Error bars are 1.5 times the interquartile range (IQR) or the maximum data point if < 1.5 IQR
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metabolites, we observed succinate and 2-hydroxyglutarate, two
metabolites related to the Krebs cycle (Fig. 1a and Supplementary
Fig. 1d). Elevated succinate levels have been previously reported
in people with DS and were interpreted as a sign of mitochondrial
dysfunction19, but succinate upregulation is also an established
marker of hypoxia and inflammation21,22. Other upregulated
metabolites included dehydroascorbate and mannitol (Fig. 1a and
Supplementary Fig. 1d), molecules involved in redox
metabolism23,24. The most significantly dysregulated metabolite
in this analysis was QA, an intermediate in the TRP catabolic
pathway that ultimately leads to synthesis of nicotinamide
adenine dinucleotide (NAD+). In fact, of the 11 measured
metabolites in the TRP pathway annotated by KEGG, we found
five to be differentially abundant in people with DS: KYN, QA,
and 5-hydroxyindoleacetate are upregulated, whereas indole and
indole-3-acetaldehyde are downregulated (Fig. 1a, b and Supple-
mentary Fig. 2a).
In vertebrate cells, there are three major catabolic pathways for
TRP, leading to the production of serotonin, NAD+, or indole
(Supplementary Fig. 2a). Conversion of TRP to KYN represents a
major pathway for catabolism of ingested TRP, eventually leading
to NAD+ production, and accounting for the removal of up to
99% of TRP not used in protein synthesis25. Remarkably, KYN
itself and the neurotoxic downstream product QA are signifi-
cantly elevated in people with DS (Fig. 1a, b). In contrast,
picolinic acid (PA), a neuroprotective derivative of KYN, is not
different between the two groups (Supplementary Fig. 2a).
Accordingly, the KYN/TRP and QA/PA ratios are both
significantly higher in people with DS (Fig. 1c).
Having revealed KP dysregulation in people with T21, we
created a third cohort of 128 plasma samples (Cohort 3, 74 T21,
54 D21; Supplementary Data 1), which partially overlapped with,
and expanded upon, Cohort 2 to validate these findings in a
quantitative manner comparable to other studies. For 124 samples
in Cohort 3, we employed a modified extraction protocol
designed to improve chromatographic separation, peak resolu-
tion, and signal intensity for TRP pathway metabolites and spiked
in stable isotopically labeled TRP and KYN, allowing for the
determination of the absolute quantities of TRP, KYN, and
several other metabolites in the pathway. This targeted quanti-
tative analysis of Cohort 3 confirmed elevated levels of KYN, QA,
and KYN/TRP ratios in people with T21 (Fig. 1d and
Supplementary Data 5 and 6). KYN levels for D21 control
samples had a median value of 2.43 μM, within the range
observed in other reports (values ranging from 712 nM to
2.95 μM26–29; Supplementary Data 7). Importantly, the median
concentration of KYN in the plasma of people with DS is
3.49 μM, higher than reported for AD26, depression27, and
lupus28, and similar to levels seen in patients with fatal cardiac
arrest29. QA levels were lower in both our D21 and T21 cohorts
relative to other studies26–29; however, the elevation in QA levels
seen in people with T21 represents the largest median fold change
associated with a medical condition among these studies (~1.9-
fold; Supplementary Data 6 and 7). TRP levels for both D21 and
T21 were in line with other studies and otherwise unremarkable.
Spearman’s rank correlation analysis between the KYN/TRP
ratios and QA levels from all individuals in Cohort 3
demonstrated a highly significant correlation between these two
parameters (Fig. 1e and Supplementary Data 8).
Finally, to assess whether the KP is dysregulated in the central
nervous system (CNS), we performed metabolomics analysis in
CSF samples from a fourth cohort (Cohort 4, 50 D21, 50 T21;
Supplementary Data 1), using the same quantitative method as
for Cohort 3. This experiment confirmed KP dysregulation in T21
as evidenced by elevated levels of TRP, L-Formylkynurenine, and
KYN itself (Fig. 1f and Supplementary Data 9 and 10).
Interestingly, despite the increased levels of TRP, the KYN/TRP
ratio is significantly elevated in the CSF of people with T21,
consistent with activation of the KP (Fig. 1f). Of note, although
QA levels were below the limit of detection in many samples (36/
50 D21, 23/50 T21), it was significantly elevated in the T21 group
(Supplementary Fig. 1e).
Altogether, these results indicate that a major metabolic impact
of T21 is dysregulation of TRP catabolism towards increased
activity in the KP. Importantly, activation of the KP has been
implicated in myriad neurological and neurodegenerative disorders,
and elevation in the KYN/TRP and QA/PA ratios have been linked
to the development of neurological conditions such as AD30–33,
Huntington’s disease34, AIDS/HIV-associated neurocognitive dis-
order35, Parkinson’s disease36, amyotrophic lateral sclerosis37,38,
and multiple sclerosis39. In addition, KYN has potent immuno-
suppressive functions40. Therefore, we focused our efforts on
elucidating the mechanisms driving activation of the KP in DS.
KP activation correlates with IDO1 and IFN-related cytokines.
To investigate potential mechanisms driving the elevated levels of
KYN and QA in people with DS, we performed transcriptome
analysis of circulating white blood cells (WBCs) in 19 adult
individuals, 10 of them with T21 (see Supplementary Data 1,
Cohort 5). We interrogated this dataset to assess possible altera-
tions in the expression levels of various enzymes catalyzing dif-
ferent reactions in the KP (see Supplementary Fig. 2a, b). This
exercise revealed a significant increase in the expression of IDO1,
the enzyme that catalyzes the rate-limiting step in the KP, in
people with DS (Fig. 2a and Supplementary Data 11). The only
other significant change observed was a decrease in KYN 3-
monooxygenase, the enzyme that converts KYN into 3-
hydroxykynurenine (Supplementary Fig. 2a–c). Given that IDO1
is a well-characterized ISG, known to be stimulated by all three
types of IFN signaling41–44, this systemic IDO1 overexpression
could be explained by our earlier finding that different immune
cell types from people with DS show consistent hyperactivation of
the IFN response12. Thus, these results indicate that the observed
activation of the KP in people with DS could be explained simply
by higher levels of IFN signaling and IDO1 overexpression.
We recently reported the results of a large plasma proteomics
study of people with DS13, which revealed that T21 causes
changes in the circulating proteome indicative of chronic
autoinflammation, including elevated levels of many cytokines
acting downstream of IFN signaling. Therefore, we tested whether
there was a correlation between levels of inflammatory cytokines
and KP activation by using a Mesoscale Discovery (MSD) assay to
measure a panel of 55 cytokines in the plasma samples from the
128 participants in Cohort 3. This analysis demonstrated
significant upregulation of many potent cytokines in people with
DS, including IL-10, IP-10, IL-6, IL-22, TNF-α, MCP-1, CRP, and
several others (Fig. 2b and Supplementary Data 12 and 13)13.
Interestingly, all four IFN ligands measured (IFN-α2a, IFN-β,
IFN-γ, and IFN-λ1/IL-29) were elevated in the population with
T21, although only IFN-α2a was significant at an FDR-adjusted
p-value on a Kolmogorov–Smirnov test of 0.05 (Supplementary
Fig. 3 and Supplementary Data 12 and 13). Comparison of our
MSD data with a comparable study of plasma cytokines in
systemic lupus erythematosus, an IFN-driven autoimmune
disorder, revealed that all 11 cytokines measured in both studies
were significantly elevated in both conditions45, supporting the
notion that the inflammatory profile of DS could be associated
with increased IFN signaling (Supplementary Data 14).
To investigate the relationship between inflammatory cytokines
and KP dysregulation, we calculated Spearman’s rank correlations
for each cytokine measured and the KYN/TRP ratio, which
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identified 31 significant correlations (Supplementary Data 15). At
the top of this list were three cytokines known to be induced by
IFN signaling, the proinflammatory molecules IP-10 (IFN-γ-
induced protein 10, CXCL10) and TNF-α, as well as the anti-
inflammatory cytokine IL-10 (Fig. 2c and Supplementary
Data 15). Furthermore, three IFN ligands were positively
correlated with the KYN/TRP ratio, albeit to a lesser degree:
IFN-γ, IFN-α2a, and IFN-λ1 (Fig. 2d and Supplementary
Data 15), each of which have been shown to induce the
expression of IDO141–44.
Taken together, these data indicate that increased KYN levels
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Fig. 2 KP activation correlates with IDO1 and IFN-related cytokines. a Scatter plot showing mRNA expression of IDO1 in white blood cells from controls
(D21) and individuals with T21. Statistical significance was calculated using DESeq2. mRNA expression values are displayed in reads per kilobase per
million (RPKM). Bars represent median, 25th, and 75th percentile values. n= 19 independent samples 10 with T21. b Heat map showing significantly
different cytokines identified in Mesoscale Discovery Assay in Cohort 3. Data from both the D21 and T21 samples were z-scored using the mean and SD
from the D21 group. Significant differences were assessed using the Kolmogorov–Smirnov test and an FDR-adjusted p-value threshold of 0.05. c Scatter
plots comparing kynurenine to tryptophan ratios to levels of the three most significantly correlated cytokines, IP-10, IL-10, and TNF-α. d Scatter plots
comparing kynurenine to tryptophan ratios to levels of three significantly correlated interferons: IFN-γ, IFN-α2a, and IFN-λ (IL-29). Spearman’s rho (ρ) and
FDR-corrected p-values are indicated for each pair. Panels b–dmeasured Cohort 3, n= 128 independent samples, 74 with T21 for panel b, n = 124 samples,
72 with T21 for panels c and d
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specific inflammatory markers in vivo, consistent with constitu-
tive IFN hyperactivity and immune dysregulation in DS.
T21 sensitizes cells to KP induction via IFNR gene dosage.
Given the wealth of potential mechanisms that could alter TRP
catabolism in individuals with DS, including differences in
medical histories, existing co-morbidities, dietary regimes, and
medication intake, we asked whether KP dysregulation could be
observed at the cellular level. Towards this end, we employed cell-
based metabolic tracing experiments using stable isotope-labeled
(13C1115N2) TRP on a panel of age- and sex-matched skin
fibroblasts derived from individuals with and without T21, both
before and after stimulation with recombinant human IFN-α2a.
Matched western blot analysis showed that T21 fibroblasts display
much stronger induction of IDO1 protein expression relative to
D21 cells (Fig. 3a, b). Remarkably, IFN-α stimulation produced a
significant, time-dependent depletion of the isotopic TRP in
T21 cells, but not supernatant (Fig. 3c, Supplementary Fig. 4a and
Supplementary Data 16), concurrent with a significant increase in
KYN levels in the supernatant, but not in cells (Fig. 3d and
Supplementary Fig. 4b). Accordingly, the KYN/TRP ratios were
most significantly elevated upon IFN-α stimulation in T21 cell
cultures, consistent with more pronounced consumption of
intracellular TRP and subsequent secretion of elevated levels of
KYN in cells of people with DS (Fig. 3e and Supplementary
Fig. 4c, d).
Next, we tested whether the observed super-induction of IDO1
and the KP by IFN-α in T21 cells is due to the extra copy of the
Type I IFNRs encoded on chr21 (IFNAR1, IFNAR2), using both
short hairpin RNA (shRNA)-mediated knockdown and CRISPR-
based knockout approaches. First, we stably knocked down
IFNAR1 expression in one of the T21 cell lines by >90% with a
specific shRNA that did not affect IFNAR2 expression (T21-
shIFNAR1; Fig. 3f). Knocking down IFNAR1 resulted in a
reproducible decrease in IFN-α-induced IDO1 expression at both
the mRNA and protein levels (Fig. 3f, g). Independently, we also
co-transduced two independent guide RNAs (gRNAs) targeting
the first exons of IFNAR1 and IFNAR2, which created a
population of T21 fibroblasts expressing ~50% of both the
IFNAR1 and IFNAR2 mRNAs relative to the parental cell line
(T21-IFNAR1/2KO; Fig. 3f). Notably, such reduction in the
expression of both Type I IFNRs completely abolished over-
expression of IDO1 mRNA and protein in response to IFN-α
stimulation, bringing it down to levels comparable to those
observed in the D21 cell line (Fig. 3f, g). We then repeated the
metabolic tracing experiment with 13C1115N2-labeled TRP on this
panel of T21 cell lines with reduced IFNR expression during a 24
h time course of IFN-α treatment. Remarkably, the T21-IFNAR1/
2KO cell line showed significantly reduced levels of KYN in both
cells and supernatants, as well as significantly reduced KYN/TRP
ratios (Fig. 3h, i and Supplementary Fig. 4e–f). Furthermore, the
T21-shIFNAR1 cell line showing intermediate IDO1 expression
displayed a partial rescue of elevated KYN levels in cells, but not
in supernatants (Fig. 3h and Supplementary Fig. 4f).
Altogether, these results indicate that IDO1 induction by IFN-α
is highly sensitivity to IFNR dosage, providing a mechanism by
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Fig. 3 T21 sensitizes cells to KP induction via IFNR gene dosage. a Western blottings demonstrating the upregulation of IDO1 over a 24 h time course in an
age- and gender-matched pair of fibroblasts with (T21) or without (D21) trisomy 21. b Western blot analysis confirming IDO1 super-induction in multiple
T21 fibroblasts after 24 h of IFN-α treatment. 1–3 are cell lines from controls, 4–6 are cell lines from individuals with trisomy 21. c Metabolic tracing
experiment using isotopolog-labeled (13C1115N2) tryptophan in fibroblast cell lines (n= 6, 3 with T21). Levels of isotopolog-labeled tryptophan in D21 and
T21 cell lysates, with or without IFN-α treatment. d Levels of isotopolog-labeled kynurenine in D21 and T21 supernatant, with or without IFN-α treatment.
e Ratio of isotopolog-labeled kynurenine in supernatant to isotopolog-labeled tryptophan levels in cells in D21 and T21 supernatant, with or without IFN-α
treatment. At each timepoint, the p-value between the untreated (IFN-) and IFN-treated (IFN+) samples was calculated using a two-tailed Student’s t-test.
f Q-RT-PCR showing relative mRNA levels of IFNAR1, IFNAR2, and IDO1, in the indicated cell lines. T21-shNon-T indicates cell line expressing a non-
targeting shRNA. T21-shIFNAR1 indicates cell line expressing a shRNA targeting IFNAR1. T21-IFNAR1/2KO indicates a cell population transduced with guide
RNAs targeting the first exons of IFNAR1 and IFNAR2. mRNA expression is expressed relative to 18S ribosomal RNA. g Western blotting showing effects of
modulating IFNAR expression as in f on induction of IDO1 protein after 6 h of IFN-α stimulation. h Levels of isotopolog-labeled kynurenine in the indicated
cell lines during a 24 h time course of IFN-α treatment. i Ratio of isotopolog-labeled kynurenine to isotopolog-labeled tryptophan levels in the indicated cell
lines during a 24 h time course of IFN-α treatment. At each timepoint, the p-value between the parental T21 cell line and each T21 cell line with modified
IFNAR expression was calculated using a two-tailed Student’s t-test. Data shown in all panels are mean ± SEM, *p < 0.05, **p < 0.01, *** p < 0.001. All
experiments were performed in triplicate for a total of n= 18
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of the KP. These results also demonstrate that KP dysregulation is
observed at the cellular level, indicating that the elevated levels of
KYN and QA in the circulation of people with DS is likely driven
by the trisomy, rather than other variables.
Tryptophan catabolism is disrupted in the Dp16 model of DS.
To test the impact of various groups of genes encoded on human
chr21 on TRP metabolism, we employed three cytogenetically
distinct mouse strains carrying segmental duplications syntenic to
human chr2146: Dp(10)1/Yey (Dp10), Dp(16)1/Yey (Dp16), and
Dp(17)1/Yey (Dp17), which have triplication of ~35 genes from
mouse chr10, ~120 genes from chr16, and ~20 genes from chr17,
respectively, and compared them with WT C5Bl/6 mice (Fig. 4a).
We prepared plasma samples from age- and sex-matched cohorts
comprising these strains and measured KYN using UHPLC-
HRMS. Interestingly, despite clear variability among individual
mice, the only strain with significantly increased plasma KYN
levels relative to WT mice was the Dp16 model, which carries the
largest segmental duplication, including the four IFNRs encoded
on human chr21: Ifnar1, Ifnar2, Ifngr2, and Il10rb (Fig. 4a, b and
Supplementary Data 17). Furthermore, we and others have pre-
viously shown that not only are the IFNRs overexpressed in this
model, but downstream IFN signaling is chronically activated on
numerous tissues including blood and brain12,47. Of note, a recent
report demonstrated elevation of KYN levels in brain tissue of the
Ts65Dn mouse model of DS, which also carries triplication of the
Ifnr gene cluster48. These results are consistent with a genetic
basis for the observed dysregulation of the KP and further
implicate triplication of the IFNR locus as a key contributor.
Finally, it is notable that the Dp16 mouse strain has the most
profound neurological impairment relative to Dp10 and Dp17.
For example, Dp16 mice have demonstrated defects in spatial
learning and memory, context-associated learning, and decreased
hippocampal long-term potentiation, not present in Dp10 or
Dp17 mice46.
Discussion
The developmental and clinical impacts of T21 in the population
with DS are diverse and highly variable, with many co-morbidities
showing increased prevalence in this population relative to typical
people. Despite many research efforts in this area, little is known
about the molecular pathways that drive the various co-
morbidities common in DS. Clearly, identification of these path-
ways could facilitate the design of diagnostic and therapeutic
strategies to serve this at-risk population via precision medicine
approaches. An obvious impact of these approaches would be in
the management of diverse neurological conditions showing
increased prevalence in this population, including, but not
restricted to, early-onset AD2,11, epilepsy49, depression50, and
autism51. Another key area of interest is in the management of
immune-related disorders. On one hand, people with DS show
increased incidence of autoimmune disorders such as autoimmune
hypothyroidism52, celiac disease8, and myriad autoimmune skin
conditions53, indicating a hyperactive immune system. Conversely,
people with DS show increased risk to specific bacterial infections,
with bacterial pneumonia being a leading cause of death4,54. Our
results point to dysregulation of the KP as a potential contributing
factor to the development of some neurological and immunolo-
gical phenotypes in people with DS, with obvious diagnostics and
therapeutic implications as described below.
People with DS constitute the largest population with a strong
predisposition to AD, which is attributed to the fact that the APP
gene is located on chr212. By age 40 years, virtually all individuals
with DS present the brain pathology of AD; however, the age of
dementia diagnoses is highly variable, with some individuals
being diagnosed in their 30s, whereas others remain dementia-
free in their 70s11. Therefore, the population with T21 provides a
unique opportunity to identify mechanisms that modulate the
impact of amyloidosis to either accelerate or delay AD develop-
ment. Interestingly, the KP has been consistently implicated in
AD progression. Multiple studies have reported elevated levels of
metabolites in the KP in people with AD and, in many of these
studies, KP dysregulation has been positively correlated with AD
progression (reviewed in ref. 55). Furthermore, IDO1 inhibition
reversed AD pathology in a mouse model of AD56. Therefore, it is
possible to hypothesize that individuals with DS showing the
strongest degree of dysregulation in the IFN→IDO1→KYN axis
may display earlier onset or faster progression of AD. Clearly,
testing this hypothesis will require a significant effort, including a
multi-dimensional, longitudinal analysis of IFN signaling, KP
dysregulation, and various metrics of the AD pathological cascade
in people with DS.
Beyond AD, it is possible that KP dysregulation is a contributor
to other neuropathologies more prevalent in DS, such as seizure
disorders, depression, and autism49–51. KYN and QA were shown
to promote seizures in mice, rats, and frogs, and QA was found to
be elevated in mouse models of epilepsy, leading to the char-
acterization of QA as an “endogenous convulsant” with a
pathogenic role in seizure disorders (reviewed in ref. 57).
Regarding depression, activation of the KP shunts TRP away
from serotonin synthesis, causing serotonin depletion, which led
Lapin and others to propose the “kynurenine hypothesis” of
depression58. Although we did not observe a significant depletion
of serotonin in our research participants with DS (Supplementary































Fig. 4 Tryptophan catabolism is disrupted in the Dp16 model of DS.
a Schematic of mouse models tested showing the localization key genes on
chromosome 21, including four of the six IFN receptors in Dp16 mice (Ifnar1,
Ifnar2, Ifngr2, and Il10rb). b Box and whisker plots showing the relative
quantification in log2 adjusted intensity of plasma kynurenine in the
indicated mouse model. p-values were calculated using a two-tailed
Student’s t-test (*p < 0.05). Boxplot shows median, 25th, and 75th
percentile values. Error bars are 1.5 times the interquartile range (IQR) or
the maximum data point if <1.5 IQR. N’s for each strain were WT−20,
Dp10–15, Dp16–20, Dp17–19
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DS diagnosed with depression show increased activation of the
KP. Notably, it has been amply documented that therapeutic
administration of IFN-α can induce depression, leading Wichers
et al.43 to propose that IDO1 induction (and consequent neuro-
toxicity) was the principal pathophysiological mechanism.
Regarding autism, independent cohort studies have documented
dysregulation of KYN metabolism in patients diagnosed with
autism spectrum disorder59,60, as demonstrated by increased
KYN/kynurenic acid ratios60 and elevated levels of QA59. KP
dysregulation could also potentially contribute to the cognitive
deficits associated with DS. The acute effects of KP metabolites,
QA in particular, on cognitive function are well-documented61,62.
QA is a potent neurotoxin that acts as an excitotoxic agonist of
NMDA receptors, which could explain the beneficial effects of
memantine, an NMDA antagonist that protects from QA-
mediated neurotoxicity, in animal models of DS63–65. Other
bioactive metabolites in the KP that were not measured in our
study, such as formic acid, could also contribute to developmental
and clinical impacts of T21. In fact, formate was recently reported
to be elevated in plasma of people with DS19. Lastly, TRP cata-
bolites produced by the gut flora such as indole and indole-3-
acetaldehyde, both of which are decreased in individuals with T21
(Supplementary Fig. 2a), were shown to suppress inflammation in
the CNS via activation of the aryl hydrocarbon receptor in
astrocytes66, demonstrating additional roles for TRP catabolites
outside of the KP in immune regulation and neurological
function.
It is important to note that the KP plays major roles in immune
control. KYN is a potent immunosuppressive metabolite pro-
moting “immune privilege” in tissues such as the brain, testes,
and gut, but which is also exploited by some tumor types to evade
immune surveillance40. KYN has complex effects on immune
cells, leading to suppression of effector CD4 and CD8 T cells,
while also inducing regulatory T cells (Tregs, reviewed in ref. 67)
and it may represent an immunosuppressive negative feedback
mechanism downstream of exacerbated IFN signaling. In fact,
Tregs have been shown to be much elevated in the circulation of
people with DS68, which could contribute to both autoimmune
conditions and poor resolution of inflammatory processes. Given
that people with DS are highly predisposed to myriad auto-
immune disorders1,5–8 and increased mortality due to pneumonia
lung infections54, our results justify future investigations to define
the role of KP dysregulation in the function of diverse immune
cell types in particular and the development of common co-
morbidities in DS in general.
Methods
Human cohorts and sample collection. All human subjects in this study were
consented according to Colorado Multiple Institutional Review Board (COMIRB)-
and Sant Pau Ethic Committee-approved protocols. Written informed consent was
obtained from parents or guardians of participants under the age of 18 years and
assent was obtained from participants over the age of 7 years, who were cognitively
able to assent. Deidentified plasma samples for Cohort 1 were obtained from the
Translational Nexus Clinical Data Registry and Biobank (University of Colorado
Anschutz Medical Campus, COMIRB #08–1276). Additional plasma and WBC
samples for Cohorts 2 and 3 were obtained through the Crnic Institute’s Human
Trisome Project (University of Colorado Anschutz Medical Campus, COMIRB
#15–2170, www.trisome.org). Cohort 4, including T21 CSF samples, was obtained
through the Down Alzheimer Barcelona Neuroimaging Initiative run at Barcelona
Down Medical Center. Control CSF samples were obtained from the Sant Pau
Initiative on Neurodegeneration cohort. All cohorts are described in Supplemen-
tary Data 1. Plasma was collected in Vacutainer tubes (EDTA—purple capped or
Lithium heparin—light green capped) and stored at −80 °C. Participant medical
history was collected by the respective biobanks. CSF samples were collected as
previously described69.
Sample extraction for metabolomics. Samples were extracted in an ice-cold
methanol:acetonitrile:water (5:3:2 v/v) solution at the following ratios: for plasma
analyses (human and mouse plasma), a volume of 20 µL was extracted in 480 µL of
the solution; for CSF analyses, a volume of 20 µL was extracted in 180 µL of the
same ice-cold solution; and for cell-based experiments, two million cells were
extracted in 1 mL of the same ice-cold lysis solution. Subsequently, these solutions
were vortexed for 30 min at 4 °C. Insoluble proteins were pelleted by centrifugation
(10 min at 4 °C and 12,000 × g) and supernatants were collected and stored at
−80 °C until analysis.
For absolute quantification experiments, 13C10 KYN and 15N2 TRP (Cambridge
Isotope Laboratories, Inc., Andover, MA) were added to the lysis solution prior to
extraction at a final concentration of 2 µM and compounds of interest were
monitored and quantified against these internal standards. For the quantitative
analysis of KP metabolites, the extraction protocol also included a final additional
step in which supernatants were further spun in a Speedvac until dry and
resuspended in 0.1% formic acid in water. This approach improves
chromatographic separation and signal intensity of metabolites in the KP, as
previously validated in technical notes70.
UHPLC-HRMS conditions for metabolomics. All UHPLC-HRMS metabolomics
analyses were performed using a Vanquish UHPLC system coupled online to a
high-resolution Q Exactive mass spectrometer (Thermo Fisher, Bremen, Ger-
many). Samples were resolved over a Kinetex C18 column (2.1 × 150 mm, 1.7 µm;
Phenomenex, Torrance, CA, USA) at 45 °C. A volume of 10 µl of sample extracts
was injected into the UHPLC-MS. Each sample was injected and run four times
with two different chromatographic and MS conditions as follows: (1) using a 5
min gradient at 450 µL/min from 5% to 95% B (A: water/0.1% formic acid; B:
acetonitrile/0.1% formic acid) and the MS was operated in positive mode and (2)
using a 5 min gradient at 450 µL/min from 5% to 95% B (A: 5% acetonitrile, 95%
water/1 mM ammonium acetate; B:95% acetonitrile/5% water, 1 mM ammonium
acetate) and the MS was operated in negative ion mode. The UHPLC system was
coupled online with a Q Exactive (Thermo, San Jose, CA, USA) scanning in Full
MS mode at 70,000 resolution in the 60–900 m/z range, 4 kV spray voltage,
15 sheath gas, and 5 auxiliary gas, operated in negative or positive ion mode
(separate runs). Calibration was performed prior to analysis using the PierceTM
Positive and Negative Ion Calibration Solutions (Thermo Fisher Scientific).
Acquired data were converted from.raw to.mzXML file format using Raw-
Converter71. To monitor possible technical variability, aliquots of each of the
individual samples were combined to make technical replicates, which were run for
both cohorts after every 15 samples. In addition, in each experiment, several lysis
solution aliquots were run as blanks for artifact identification. Coefficients of
variations (CV= SD/mean) were calculated for each metabolite across tech mixes
and only metabolites with CVs < 20% were considered for this manuscript.
Metabolomics data processing. Metabolite assignments to KEGG compounds,
isotopolog distributions, and correction for expected natural abundances of 13C
and 15N isotopes, were performed using MAVEN (Princeton, NJ, USA) on the
basis of accurate intact mass, high-resolution-based determination of chemical
formulae, retention times against an in-house standard library of ~1000
compounds72,73. Relative quantification was performed in both positive and
negative ion modes, according to the ionizability of each metabolite—as deter-
mined against an in-house standard library of ~1000 compounds, as validated in
previous technical notes74,75. Peak areas were exported for further statistical ana-
lysis with R (R Foundation for Statistical Computing, Vienna, Austria). Data sets
from exploratory, untargeted analyses were log2 transformed. Subsequent data
preprocessing included filtering out metabolites with low-intensity values (per-
metabolite threshold informed by blanks) that were detected in <90% of the
T21 samples or <90% of the D21 samples, leaving 91 metabolites for further
analyses. To perform differential expression analysis, the limma R package
(v3.32.10) was used to fit a linear model to the data with age, sex, and cohort as
covariates16. Log2 fold change, p-value and adjusted p-value were calculated for the
T21–D21 comparison using an unmoderated Student’s t-test and the FDR method
for multiple testing correction17. Adjusted p-values are shown in the volcano plots
and reported on the boxplots. For displaying data per sample on the boxplots, we
plotted the adjusted intensity values for each metabolite produced by the remo-
veBatchEffects function in the limma R package using age, sex, and cohort as
covariates. Stable isotope-labeled TRP and KYN from tracing experiments were
monitored in positive ion mode. Isotopolog distributions in tracing experiments
with 13C1115N2-TRP were also manually analyzed with MAVEN (Princeton,
NJ, USA).
Calculation of absolute quantification data. Calculation of absolute quantifica-
tion for KP metabolites was performed using the following formula: [light]=
(abundance light)/(abundance heavy)*[heavy] [dilution factor] where [light]=
concentration of non-isotopic metabolite, (abundance light)= total area abun-
dance of non-isotopic metabolite, (abundance heavy)= total area abundance of
isotopic metabolite, and [heavy]= known concentration isotopic metabolite.
RNA-seq sample prep. Peripheral blood was collected in EDTA vacutainer tubes
(BD, 366643) from ten individuals with T21 and nine D21 controls. Blood was
centrifuged at 500 × g for 15 min to separate plasma, buffy coat, and red blood cells.
WBCs were isolated from the buffy coat fraction by RBC lysis and washed with our
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sorting buffer (see below) according to the manufacturer’s instructions (BD,
555899). WBCs were cryopreserved in CryoStor CS10 Freezing Media (210102) at
~10 million cells/mL. WBCs were quickly thawed at 37 °C and immediately spiked
into 9 mL of sorting media and centrifuged at 500 × g for 5 min and the media
removed. Cells were lysed in 600 µL RLT plus (Qiagen) and β-mercaptoethanol
(BME) lysis buffer (10 µL BME:1 mL RLT plus). RNA was extracted using the
AllPrep DNA/RNA/Protein Mini Kit according to the manufacturer’s instructions
(Qiagen, 80004). RNA quality was determined by Agilent 2200 TapeStation and
quantified by Qubit (Life Technologies). Samples with RIN of 6.8 or greater and a
minimum of 1 µg were sent to Novogene for stranded library prep and 2 × 150
paired-end sequencing.
RNA-seq data analysis. Analysis of library complexity and high per-base
sequence quality across all reads (i.e., q > 30) was performed using FastQC (v0.11.5)
software (Andrews 2010). Low-quality bases (q < 10) were trimmed from the 3′-
end of reads and short reads (<30 nt after trimming), and adaptor sequences were
removed using the fastqc-mcf (v1.05) tool from ea-utils. Common sources of
sequence contamination such as mycoplasma, mitochondria, and ribosomal RNA
were identified and removed using FASTQ Screen (v0.9.1). Reads were aligned to
GRCh37/hg19 using TopHat2 (v2.1.1,–b2-sensitive–keep-fasta-order–no-coverage-
search–max-multihits 10–library-type fr-firststrand). High-quality mapped reads
(MAPQ > 10) were filtered with SAMtools (v1.5). Reads were sorted with Picard-
tools (v2.9.4) (SortSAM) and duplicates marked (MarkDuplicates). Quality control
of final reads was performed using RSeQC (v2.6.4). Gene-level counts were
obtained using HTSeq (v0.8.0,–stranded= reverse –minaqual= 10 –type= exon
–idattr= gene_id–mode= intersection-nonempty, GTF-ftp://igenome:G3nom3-
s4u@ussd-ftp.illumina.com/Homo_sapiens/UCSC/hg19/ Homo_-
sapiens_UCSC_hg19.tar.gz). Differential expression was determined using DESeq2
(v1.18.1) and R (v3.4.3).
Cell culture. Human fibroblasts cell lines GM08447, GM02036, GM05659,
GM04616, GM02767, and AG05397 were described previously12. For the metabolic
tracing experiment, cells were cultured in 5 mg/L 13C1115N2 L-tryptophan (Sigma-
Aldrich, 574597) for 72 h prior to stimulation with 10 ng/mL IFN-α2a (R&D
Systems, 11101–2). Media was prepared by adding 120 µL of 10 mg/mL stock
13C1115N2 L-tryptophan in 1× phosphate-buffered saline (PBS) to 240 mL of RPMI
(Corning, 10–040) in 10% dialyzed fetal bovine serum (FBS) (Sigma, F0392) and
1× Anti-Anti (Gibco, 15240–062). Cells were treated with 10 ng/mL IFN-α2a or
vehicle by adding 6 µL of 0.2 mg/mL IFN-α2a or 1× PBS to 120 mL of isotopolog-
labeled media. Cell lysates and media were collected at 0, 1, 6, and 24 h following
initial application of the isotopolog-labeled TRP and IFN-α2a. LC-MS metabo-
lomics profiling was performed as described above and TRP catabolites were
identified by their 13C15N peaks.
Generation of shRNA and CRISPR cell lines. To generate lentiviral particles,
three million HEK293FT cells were transfected with 10 µg shIFNAR1
(TRCN0000059013, 5′-GCCAAGATTCAGGAAATTATT-3′), IFNAR1 gRNA
(Human GeCKO Library A 22695, 5′-AACAGGAGCGATGAGTCTGT-3′), or
IFNAR2 gRNA (Human GeCKO Library A 22697, 5′-GTGTATATCAGCCTCG
TGTT-3′) plasmid, and 10 µg of packaging viral mix (3:1 pD8.9:pCMV-VSVG)
using PEI in a 10 cm plate. Freshly collected lentiviral particles (2 mL) were then
used to transduce 1.0e5 GM02767 cells in each well of a six-well plate. The cells
were expanded to 10 cm plates before starting puromycin selection (1 µg/mL).
IFN stimulations of fibroblasts and western blottings. Cells were plated at equal
densities (~33,000/cm2) and were allowed to attach overnight. The next day, IFN-
α2a (R&D Systems, 11101–2) was added at 10 ng/mL in RPMI (Corning, 10–040)
and cells were collected by 0.25% trypsin (Gibco, 25200–056) at 0, 1, 6, and 24 h.
Trypsin was quenched by adding RPMI with 10% Dialyzed FBS (Sigma, F0392).
Cells were pelleted at 200 × g for 5 min. Cell pellets were washed with 1× PBS, then
resuspended in RIPA buffer containing 1 μg/mL pepstatin, 2 μg/mL aprotinin,
20 μg/mL trypsin inhibitor, 10 nM leupeptin, 200 nM Na3VO4, 500 nM phe-
nylmethylsulfonyl fluoride, and 10 μM NaF. Suspensions were sonicated at 6 watts
for 15 s two times and clarified by centrifugation at 21,000 × g for 10 min at 4 °C.
Supernatants were quantified in a Pierce BCA Protein Assay and diluted in
complete RIPA with 4× Laemmli sample buffer. Tris-glycine SDS-polyacrylamide
gel electrophoresis was used to separate 20–40 μg protein lysate, which was
transferred to a 0.45 μm polyvinylidene fluoride membrane. Membranes were
blocked in 5% non-fat dried milk or 2.5% bovine serum albumin (BSA) in Tris-
buffered saline containing 0.1% TWEEN (TBS-T) at room temperature for 30 min.
Immunoblotting was done using primary antibodies against IDO1 (1:1000, Cell
Signaling Technology, Catalog Number 86630) and GAPDH (1:5000, Santa Cruz
Biotechnology, Catalog Number 365062) overnight in 5% non-fat dried milk or
2.5% BSA in TBS-T at 4 °C, while shaking. Membranes were washed 3× in TBS-T
for 5–15 min before probing with a horseradish peroxidase-conjugated secondary
antibody in 5% non-fat dried milk at room temperature for 1 h. Membranes were
again washed 3× in TBS-T for 5–15 min before applying enhanced chemilumi-
nescence solution. Chemiluminensence signal was captured using a GE (Pittsburgh,
PA) ImageQuant LAS4000.
Quantitative reverse-transcription PCR. Total RNA was collected from cells
using TRIzol (Life Technologies/Thermo Fisher Scientific) and reverse transcrip-
tion was carried out using the Applied Biosystems High Capacity cDNA kit (Life
Technologies/Thermo Fisher Scientific). Quantitative PCR was carried out with
reference to a standard curve using SYBR Select Master Mix for CFX (Life Tech-
nologies/Thermo Fisher Scientific) on a Viia7 Real-Time PCR system (Life Tech-
nologies/Thermo Fisher Scientific) and was normalized to 18S rRNA signals.
Primers used for quantitative reverse-transcription PCR were as follows (5′ to 3′):
18S-F, GCCGCTAGAGGTGAAATTCTTG; 18S-R, CTTTCGCTCTGGTCCGTC
TT; IDO1-F, CCGTAAGGTCTTGCCAAGAAATA; IDO1-R, GTCAGGGGCTT
ATTAGGATCC; IFNAR1-F, GATTATCAAAAAACTGGGATGG; IFNAR1-R, C
CAATCTGAGCTTTGCGAAATGG; IFNAR2-F, GGTTCTCATGGTGTATATC
AGC; IFNAR2-R, GCAAGATTCATCTGTGTAATCAGG.
Fibroblast TRP-tracing experiment data analysis. Prior to plotting, tracing
experiment data were batch-adjusted and measurements from biological replicates
were summarized on time-course plots as the mean value of the replicates ± SEM.
P-values were calculated in R with a Student’s t-test and used the FDR method for
multiple testing correction.
Mesoscale Discovery assay. The Mesoscale Discovery Human Biomarker 54-
Plex was combined with U-Plex reagents for IFN-α2a, IFN-β, and IL-29 (IFN-λ), to
measure a total of 55 unique cytokines from 500 μL of plasma from each of the 128
individuals in Cohort 3, as per the manufacturer’s instructions. To visualize the
effect of karyotype on each cytokine, the MSD data from both the D21 and
T21 samples were z-scored using the mean and SD from the D21 group. Sig-
nificantly differentially expressed cytokines were determined using the
Kolmogorov–Smirnov test in R and an FDR-adjusted p-value threshold of 0.05.
Prior to correlation analyses, both MSD data and metabolomics data were adjusted
for age and sex using the linear model-fitting procedure described above. Spear-
man’s rank correlations and p-values were calculated in R using the cor.test
function. Adjusted p-values used FDR for multiple testing correction.
Mouse strains and data analysis. Dp(10Prmt2-Pdxk)1Yey/J (Dp(10)1Yey/+ ),
Dp(16Lipi-Zbtb21)1Yey/J (Dp(16)1Yey/+ ), and Dp(17Abcg1-Rrp1b)1(Yey)/J
(Dp(17)1Yey/+ ) have been previously described46. Dp(16) mice were purchased
from Jackson Laboratories or provided by Drs Faycal Guedj and Diana Bianchi at
the National Institutes of Health. Dp(10)1Yey/+ , and Dp(17)1Yey/+mice were
provided by Drs Katheleen Gardiner and Santos Franco, respectively. Animals were
used between 6 and 30 weeks of age. All mice were maintained on a C57Bl/6
background and housed in specific pathogen-free conditions. All experiments were
approved by the Institutional Animal Care and Use Committee at the University of
Colorado Anschutz Medical Campus. Prior to plotting and testing for statistical
significance, mouse metabolomics data were adjusted for batch and sex using the
linear modeling procedure described above. P-values were calculated in R with a
Student’s t-test and used FDR for multiple testing correction.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The source data for Fig. 3a, b, f, g are provided as a Source Data file. All other figures
were generated using data proved in Supplementary Data and/or deposited into publicly
available databases. RNA-seq data were deposited at the Gene Expression Omnibus
(National Center for Biotechnology Information) with series accession number
GSE128622. Metabolomics data were deposited in the Metabolomics Workbench
database with Study IDs ST001240, ST001241, ST001242, and ST001243. The data and
code at https://github.com/CostelloLab/Trisomy21_KYN_metabolomics can be used to
generate Figs. 1, 2, and 4, as well as the metabolomics portions of Fig. 3.
Code availability
All data and R code developed for the full set of statistical metabolomic analyses is
available at: https://github.com/CostelloLab/Trisomy21_KYN_metabolomics. To ensure
reproducibility, this code can be run to generate all figures for this manuscript.
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